Landiolol Hydrochloride Orpha-Devel

Landiolol Hydrochloride, the active ingredient in Landiolol Hydrochloride Orpha‑Devel, is a beta‑blocker presented as an injectable solution for intravenous use. It is employed to manage supraventricular tachycardia, atrial fibrillation and atrial flutter in acute care settings.

GNH USA supplies Landiolol Hydrochloride Orpha‑Devel as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Landiolol Hydrochloride is a short‑acting β1‑adrenergic blocker used in cardiac rhythm management. - Supraventricular tachycardia: rapid reduction of ventricular rate and facilitation of conversion to sinus rhythm. - Atrial fibrillation: control of ventricular response during acute episodes. - Atrial flutter: decrease of heart rate to improve hemodynamic stability.

Adverse reactions may occur with intravenous administration of landiolol.

Common Side Effects: - Bradycardia: excessively low heart rate. - Hypotension: drop in blood pressure. - Dizziness or light‑headedness. - Fatigue or weakness. - Nausea. - Injection site irritation.

Serious or Rare Side Effects: - Severe bronchospasm in patients with reactive airway disease. - Acute heart failure due to excessive negative inotropy. - Cardiogenic shock. - Allergic reactions such as rash, urticaria, or anaphylaxis.

When using landiolol, clinicians should consider several safety measures. - Cardiac monitoring: continuous ECG and blood pressure observation during infusion. - Dose adjustment: reduce or discontinue if severe bradycardia or hypotension develops. - Respiratory caution: avoid in patients with severe asthma or COPD without specialist input. - Drug interactions: review concomitant medications that affect heart rate or blood pressure. - Pregnancy and lactation: use only if the potential benefit justifies the potential risk, as data are limited. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Landiolol may interact with other cardiovascular agents and drugs affecting its metabolism.

Major Interactions (Avoid): - Other β‑blockers: additive negative chronotropic and inotropic effects. - Calcium channel blockers (e.g., verapamil, diltiazem): heightened risk of bradycardia and AV block. - Digoxin: increased risk of atrioventricular conduction disturbances.

Moderate Interactions (Monitor Closely): - Antihypertensives (ACE inhibitors, ARBs): possible additive hypotensive effect. - Anesthetic agents (e.g., propofol, volatile anesthetics): may enhance cardiovascular depression. - Diuretics: monitor electrolytes and volume status to avoid excessive hypotension.